Tags

Type your tag names separated by a space and hit enter

Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
JAMA Neurol 2015; 72(9):1029-42JN

Abstract

IMPORTANCE

Individuals in the presymptomatic stage of Alzheimer disease (AD) are increasingly being targeted for AD secondary prevention trials. How early during the normal life span underlying AD pathologies begin to develop, their patterns of change over time, and their relationship with future cognitive decline remain to be determined.

OBJECTIVE

To characterize the within-person trajectories of cerebrospinal fluid (CSF) biomarkers of AD over time and their association with changes in brain amyloid deposition and cognitive decline in cognitively normal middle-aged individuals.

DESIGN, SETTING, AND PARTICIPANTS

As part of a cohort study, cognitively normal (Clinical Dementia Rating [CDR] of 0) middle-aged research volunteers (n = 169) enrolled in the Adult Children Study at Washington University, St Louis, Missouri, had undergone serial CSF collection and longitudinal clinical assessment (mean, 6 years; range, 0.91-11.3 years) at 3-year intervals at the time of analysis, between January 2003 and November 2013. A subset (n = 74) had also undergone longitudinal amyloid positron emission tomographic imaging with Pittsburgh compound B (PiB) in the same period. Serial CSF samples were analyzed for β-amyloid 40 (Aβ40), Aβ42, total tau, tau phosphorylated at threonine 181 (P-tau181), visinin-like protein 1 (VILIP-1), and chitinase-3-like protein 1 (YKL-40). Within-person measures were plotted according to age and AD risk defined by APOE genotype (ε4 carriers vs noncarriers). Linear mixed models were used to compare estimated biomarker slopes among middle-age bins at baseline (early, 45-54 years; mid, 55-64 years; late, 65-74 years) and between risk groups. Within-person changes in CSF biomarkers were also compared with changes in cortical PiB binding and progression to a CDR higher than 0 at follow-up.

MAIN OUTCOMES AND MEASURES

Changes in Aβ40, Aβ42, total tau, P-tau181, VILIP-1, and YKL-40 and, in a subset of participants, changes in cortical PiB binding.

RESULTS

While there were no consistent longitudinal patterns in Aβ40 (P = .001-.97), longitudinal reductions in Aβ42 were observed in some individuals as early as early middle age (P ≤ .05) and low Aβ42 levels were associated with the development of cortical PiB-positive amyloid plaques (area under receiver operating characteristic curve = 0.9352; 95% CI, 0.8895-0.9808), especially in mid middle age (P < .001). Markers of neuronal injury (total tau, P-tau181, and VILIP-1) dramatically increased in some individuals in mid and late middle age (P ≤ .02), whereas the neuroinflammation marker YKL-40 increased consistently throughout middle age (P ≤ .003). These patterns were more apparent in at-risk ε4 carriers (Aβ42 in an allele dose-dependent manner) and appeared to be associated with future cognitive deficits as determined by CDR.

CONCLUSIONS AND RELEVANCE

Longitudinal CSF biomarker patterns consistent with AD are first detectable during early middle age and are associated with later amyloid positivity and cognitive decline. Such measures may be useful for targeting middle-aged, asymptomatic individuals for therapeutic trials designed to prevent cognitive decline.

Authors+Show Affiliations

Knight Alzheimer's Disease Research Center, Washington University, St Louis, Missouri2Department of Neurology, Washington University, St Louis, Missouri3Hope Center for Neurodegenerative Disorders, Washington University, St Louis, Missouri.Knight Alzheimer's Disease Research Center, Washington University, St Louis, Missouri4Division of Biostatistics, Washington University, St Louis, Missouri.Knight Alzheimer's Disease Research Center, Washington University, St Louis, Missouri2Department of Neurology, Washington University, St Louis, Missouri3Hope Center for Neurodegenerative Disorders, Washington University, St Louis, Missouri.Department of Pathology and Immunology, Washington University, St Louis, Missouri.Knight Alzheimer's Disease Research Center, Washington University, St Louis, Missouri4Division of Biostatistics, Washington University, St Louis, Missouri.Knight Alzheimer's Disease Research Center, Washington University, St Louis, Missouri6Department of Radiology, Washington University, St Louis, Missouri.Knight Alzheimer's Disease Research Center, Washington University, St Louis, Missouri6Department of Radiology, Washington University, St Louis, Missouri.ADx NeuroSciences, Ghent, Belgium.ADx NeuroSciences, Ghent, Belgium.EUROIMMUN, Lübeck, Germany.Fujirebio US, Malvern, Pennsylvania.Fujirebio Europe, Ghent, Belgium.Department of Pathology and Immunology, Washington University, St Louis, Missouri.Knight Alzheimer's Disease Research Center, Washington University, St Louis, Missouri2Department of Neurology, Washington University, St Louis, Missouri3Hope Center for Neurodegenerative Disorders, Washington University, St Louis, Missouri.Knight Alzheimer's Disease Research Center, Washington University, St Louis, Missouri2Department of Neurology, Washington University, St Louis, Missouri3Hope Center for Neurodegenerative Disorders, Washington University, St Louis, Missouri.Knight Alzheimer's Disease Research Center, Washington University, St Louis, Missouri2Department of Neurology, Washington University, St Louis, Missouri3Hope Center for Neurodegenerative Disorders, Washington University, St Louis, Missouri.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26147946

Citation

Sutphen, Courtney L., et al. "Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age." JAMA Neurology, vol. 72, no. 9, 2015, pp. 1029-42.
Sutphen CL, Jasielec MS, Shah AR, et al. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. JAMA Neurol. 2015;72(9):1029-42.
Sutphen, C. L., Jasielec, M. S., Shah, A. R., Macy, E. M., Xiong, C., Vlassenko, A. G., ... Fagan, A. M. (2015). Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. JAMA Neurology, 72(9), pp. 1029-42. doi:10.1001/jamaneurol.2015.1285.
Sutphen CL, et al. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. JAMA Neurol. 2015;72(9):1029-42. PubMed PMID: 26147946.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. AU - Sutphen,Courtney L, AU - Jasielec,Mateusz S, AU - Shah,Aarti R, AU - Macy,Elizabeth M, AU - Xiong,Chengjie, AU - Vlassenko,Andrei G, AU - Benzinger,Tammie L S, AU - Stoops,Erik E J, AU - Vanderstichele,Hugo M J, AU - Brix,Britta, AU - Darby,Heather D, AU - Vandijck,Manu L J, AU - Ladenson,Jack H, AU - Morris,John C, AU - Holtzman,David M, AU - Fagan,Anne M, PY - 2015/7/7/entrez PY - 2015/7/7/pubmed PY - 2015/12/15/medline SP - 1029 EP - 42 JF - JAMA neurology JO - JAMA Neurol VL - 72 IS - 9 N2 - IMPORTANCE: Individuals in the presymptomatic stage of Alzheimer disease (AD) are increasingly being targeted for AD secondary prevention trials. How early during the normal life span underlying AD pathologies begin to develop, their patterns of change over time, and their relationship with future cognitive decline remain to be determined. OBJECTIVE: To characterize the within-person trajectories of cerebrospinal fluid (CSF) biomarkers of AD over time and their association with changes in brain amyloid deposition and cognitive decline in cognitively normal middle-aged individuals. DESIGN, SETTING, AND PARTICIPANTS: As part of a cohort study, cognitively normal (Clinical Dementia Rating [CDR] of 0) middle-aged research volunteers (n = 169) enrolled in the Adult Children Study at Washington University, St Louis, Missouri, had undergone serial CSF collection and longitudinal clinical assessment (mean, 6 years; range, 0.91-11.3 years) at 3-year intervals at the time of analysis, between January 2003 and November 2013. A subset (n = 74) had also undergone longitudinal amyloid positron emission tomographic imaging with Pittsburgh compound B (PiB) in the same period. Serial CSF samples were analyzed for β-amyloid 40 (Aβ40), Aβ42, total tau, tau phosphorylated at threonine 181 (P-tau181), visinin-like protein 1 (VILIP-1), and chitinase-3-like protein 1 (YKL-40). Within-person measures were plotted according to age and AD risk defined by APOE genotype (ε4 carriers vs noncarriers). Linear mixed models were used to compare estimated biomarker slopes among middle-age bins at baseline (early, 45-54 years; mid, 55-64 years; late, 65-74 years) and between risk groups. Within-person changes in CSF biomarkers were also compared with changes in cortical PiB binding and progression to a CDR higher than 0 at follow-up. MAIN OUTCOMES AND MEASURES: Changes in Aβ40, Aβ42, total tau, P-tau181, VILIP-1, and YKL-40 and, in a subset of participants, changes in cortical PiB binding. RESULTS: While there were no consistent longitudinal patterns in Aβ40 (P = .001-.97), longitudinal reductions in Aβ42 were observed in some individuals as early as early middle age (P ≤ .05) and low Aβ42 levels were associated with the development of cortical PiB-positive amyloid plaques (area under receiver operating characteristic curve = 0.9352; 95% CI, 0.8895-0.9808), especially in mid middle age (P < .001). Markers of neuronal injury (total tau, P-tau181, and VILIP-1) dramatically increased in some individuals in mid and late middle age (P ≤ .02), whereas the neuroinflammation marker YKL-40 increased consistently throughout middle age (P ≤ .003). These patterns were more apparent in at-risk ε4 carriers (Aβ42 in an allele dose-dependent manner) and appeared to be associated with future cognitive deficits as determined by CDR. CONCLUSIONS AND RELEVANCE: Longitudinal CSF biomarker patterns consistent with AD are first detectable during early middle age and are associated with later amyloid positivity and cognitive decline. Such measures may be useful for targeting middle-aged, asymptomatic individuals for therapeutic trials designed to prevent cognitive decline. SN - 2168-6157 UR - https://www.unboundmedicine.com/medline/citation/26147946/Longitudinal_Cerebrospinal_Fluid_Biomarker_Changes_in_Preclinical_Alzheimer_Disease_During_Middle_Age_ L2 - https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2015.1285 DB - PRIME DP - Unbound Medicine ER -